Tumour-specific delivery of ω-conotoxin MVIIA via engineered Salmonella for safe anticancer therapy

These findings demonstrate the potential of MVIIA-secreting Salmonella spp. as a novel drug delivery platform to address the key limitations of conventional therapies. This strategy provides a foundation for advancing bacterial-mediated treatments in oncology, with broad applicability to various solid tumours and the potential for integration into combination therapies.